Federal Register / Vol. 75, No. 90 / Tuesday, May 11, 2010 / Notices 26257 

ESTIMATE OF ANNUALIZED BURDEN HOURS—Continued 

Respondents 

state epidemiologists Number of 

respondents 

Number of 

responses per 

respondent 

Average burden 

per response 

(in hours) Form 

National Respiratory & Enteric Virus Surveillance System (NREVSS) .......................... 90 52 10/60 

Rabies (electronic) ........................................................................................................... 50 12 8/60 

Rabies (paper) ................................................................................................................. 3 12 15/60 

Waterborne Diseases Outbreak Form ............................................................................. 57 1 20/60 

Cholera and other Vibrio illnesses .................................................................................. 450 1 20/60 

Outbreak Report of Suspected Viral Gastroenteritis (Clicivirus surveillance) ................. 20 5 5/60 

Listeria Case Form .......................................................................................................... 53 1 30/60 

HABISS data entry form .................................................................................................. 10 12 8

HABISS monthly reporting form ...................................................................................... 10 12 30/60 

Dated: May 5, 2010. 

Maryam I. Daneshvar, 

Acting Reports Clearance Officer, Centers for 

Disease Control and Prevention. 

[FR Doc. 2010–11178 Filed 5–10–10; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[30Day-10–09BQ] 

Agency Forms Undergoing Paperwork 

Reduction Act Review 

The Centers for Disease Control and 

Prevention (CDC) publishes a list of 

information collection requests under 

review by the Office of Management and 

Budget (OMB) in compliance with the 

Paperwork Reduction Act (44 U.S.C. 

Chapter 35). To request a copy of these 

requests, call the CDC Reports Clearance 

Officer at (404) 639–5960 or send an email to omb@cdc.gov. Send written 

comments to CDC Desk Officer, Office of 

Management and Budget, Washington, 

DC or by fax to (202) 395–5806. Written 

comments should be received within 30 

days of this notice. 

Proposed Project 

Examining In-vehicle Exposures to 

Air Pollutants and Corresponding 

Health Outcomes of Commuters— 

New—National Center for 

Environmental Health, (NCEH) and 

Agency for Toxic Substances and 

Disease Registry (ATSDR), Centers for 

Disease Control and Prevention, (CDC). 

Background and Brief Description 

Numerous studies have found 

associations between ambient fine 

particulate matter (PM2.5) and adverse 

cardiovascular outcomes. Several recent 

epidemiologic studies suggest that 

vehicle-related emissions, in particular, 

may be linked to many of the these 

adverse effects and that specific subpopulations may be more susceptible to 

health risks due to their enhanced 

exposures to vehicle-related PM2.5

sources. Commuters are a potentially 

susceptible, yet poorly characterized, 

sub-population. Importantly, recent 

epidemiologic studies indicate that 

specific sub-groups, including those 

with asthma, may be at risk to cardio 

respiratory health effects due to their 

pre-existing health condition. A more 

complete understanding of in-vehicle 

exposures for the commuter population, 

especially those with asthma, is 

therefore becoming increasingly 

necessary as commuting durations and 

roadway congestion have steadily 

increased throughout the U.S. during 

the last 20 years. The National Center 

for Environmental Health (NCEH), 

Centers for Disease Control and 

Prevention (CDC) will conduct this 

study to characterize in-vehicle 

exposures to traffic-related air 

pollutants among commuters, with and 

without asthma, and any health impacts 

that these exposures may have on the 

commuter. 

A total of 40 participants (20 adults 

with physician-diagnosed asthma and 

20 healthy adults) living in the Atlanta 

metro area will be recruited for 

participation in this study. Participants 

will be excluded if they meet specific 

criteria including: ever being diagnosed 

with severe asthma, ever suffering a 

myocardial infarction, smoking tobacco 

products, or ever being diagnosed with 

a pulmonary disease such as 

emphysema, chronic obstructive 

pulmonary disorder (COPD), or any type 

of lung cancer, will be excluded. 

Prior to their scheduled commute, 

participants will complete a one-time 

baseline questionnaire to assess medical 

history and general exposures. 

Additionally, a short symptom diary 

recording any respiratory symptoms 

will be completed by the participant 

prior to the commute and health 

measurements for lung function, lung 

inflammatory markers, heart rate, and 

biomarkers of systemic inflammation 

will be conducted by a trained field 

technician. In-vehicle exposures to 

particulate matter and other air 

pollutants will then be measured for all 

participants during their commute. 

After the commute, the symptom diary 

and health measurements will be 

conducted again to assess any potential 

changes in respiratory and 

cardiovascular health effects. Each 

participant will conduct the commute 

two times during the study year. The 

information learned from the health 

measurements and diary entries before 

and after the commute will be important 

in better understanding the potential 

acute health impacts associated with 

exposures to in-vehicle traffic pollutants 

and respiratory and cardiovascular 

health, and whether urban commuters— 

especially those with asthma—should 

be viewed as a susceptible subpopulation given their enhanced 

exposures to PM2.5 and gas-phase 

pollutants. 

There is no cost to participants other 

than their time. The estimated annual 

burden hours are 180 hours. 


emcdonald on DSK2BSOYB1PROD with NOTICES
26258 Federal Register / Vol. 75, No. 90 / Tuesday, May 11, 2010 / Notices 

ESTIMATED ANNUALIZED BURDEN HOURS

Respondents Instrument type No. of 

respondents 

No. of 

responses per 

respondent 

Average 

burden per 

respondent 

(in hours) 

Eligible participants ......................................... Baseline questionnaire ................................... 40 1 20/60 

Symptom survey ............................................ 40 5 2/60 

Scripted commute data collection .................. 40 2 2 

Dated: May 5, 2010. 

Maryam I. Daneshvar, 

Reports Clearance Officer, Centers for Disease 

Control and Prevention. 

[FR Doc. 2010–11180 Filed 5–10–10; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Office of the Director; Notice of Charter 

Renewal for the National Science 

Advisory Board for Biosecurity 

In accordance with Title 41 of the 

U.S. Code of Federal Regulations, 

Section 102–3.65(a), notice is hereby 

given that the Charter for the National 

Science Advisory Board for Biosecurity 

(NSABB) was renewed for an additional 

two-year period on April 7, 2010. 

It is determined that NSABB is in the 

public interest in connection with the 

performance of duties imposed on the 

Department of Health and Human 

Services by law, and that these duties 

can best be performed through the 

advice and counsel of this group. 

Inquiries may be directed to Jennifer 

Spaeth, Director, Office of Federal 

Advisory Committee Policy, Office of 

the Director, National Institutes of 

Health, 6701 Democracy Boulevard, 

Suite 1000, Bethesda, Maryland 20892 

(Mail code 4875), Telephone (301) 496– 

2123, or spaethj@od.nih.gov. 

Dated: May 4, 2010. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2010–11043 Filed 5–10–10; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

Public Health Service, HHS. 

ACTION: Notice. 

SUMMARY: The inventions listed below 

are owned by an agency of the U.S. 

Government and are available for 

licensing in the U.S. in accordance with 

35 U.S.C. 207 to achieve expeditious 

commercialization of results of 

federally-funded research and 

development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. 

ADDRESSES: Licensing information and 

copies of the U.S. patent applications 

listed below may be obtained by writing 

to the indicated licensing contact at the 

Office of Technology Transfer, National 

Institutes of Health, 6011 Executive 

Boulevard, Suite 325, Rockville, 

Maryland 20852–3804; telephone: 301/ 

496–7057; fax: 301/402–0220. A signed 

Confidential Disclosure Agreement will 

be required to receive copies of the 

patent applications. 

Erythroid Progenitor Cell Line for 

Hematological Disease Applications 

Description of Invention: Plasmodium 

vivax (malaria) is a significant health 

concern in many parts of Asia, Latin 

America, North Africa, and the Middle 

East. There is a lack of continuous 

culture systems for this pathogen. The 

subject technology is an erythroid 

progenitor continuous cell line (termed 

CD36E) identified by erythroid markers 

CD36, CD33, CD44, CD71, CD235, and 

globoside. These CD36E cells are 

heterozygous for Fya and Fyb (Duffy 

antigen). Due to recent evidence that 

Plasmodium vivax (P. vivax) can infect 

erythroid progenitor cells (reference: YX 

Ru et al. and T Panichakul et al.), these 

cells can be potentially used for 

culturing P. vivax and other species of 

malaria. This in turn could aid 

development of malaria related 

treatments and/or products. In addition, 

the cell line can also be used for other 

hematological disease applications that 

involve red blood cells or red blood cell 

precursors. The CD36E cells also 

produce alpha, beta, and chi 

hemoglobin and therefore may be used 

for research involving hemoglobin. 

Applications: 

• Culture system for Plasmodium 

species (malaria) 

• Hematological diseases 

Advantages: Immortalized erythroid 

progenitor cell line. 

Development Status: In vitro data can 

be provided upon request. 

Market: 

• Malaria 

• Anti-malaria drug screening 

• Hematological diseases 

• Hemoglobin 

Inventors: Susan Wong, Neal S. 

Young, Ning Zhi (NHLBI). 

Relevant Publications: 

1. YX Ru et al. Invasion of 

erythroblasts by Pasmodium vivax: A 

new mechanism contributing to malarial 

anemia. Ultrastruct Pathol. 2009 

Oct;33(5):236–242. [PubMed: 

19895296]. 

2. T Panichakul et al. Production of 

erythropoietic cells in vitro for 

continuous culture of Plasmodium 

vivax. Int J Parasitol. 2007 

Dec;37(14):1551–1557. [PubMed: 

17610880]. 

Patent Status: HHS Reference No. E– 

151–2010/0—Research Tool. Patent 

protection is not being pursued for this 

technology. 

Licensing Status: Available for 

biological materials licensing. 

Licensing Contact: Kevin W. Chang, 

Ph.D.; 301–435–5018; 

changke@mail.nih.gov. 

Collaborative Research Opportunity: 

The National Heart Lung and Blood 

Institute, Hematology Branch, is seeking 

statements of capability or interest from 

parties interested in collaborative 

research to further develop, evaluate, or 

commercialize the CD36E cell line. 

Please contact Cecilia Pazman, Ph.D., at 

pazmance@mail.nih.gov for more 

information. 

Parvovirus B19 Codon Optimized 

Structural Proteins for Vaccine and 

Diagnostic Applications 

Description of Invention: Parvovirus 

B19 (B19V) is the only known 

pathogenic human parvovirus. Infection 

by this viral pathogen can cause 

transient aplastic crisis in individuals 

with high red cell turnover, pure red 

cell aplasia in immunosuppressed 

patients, and hydrops fetalis during 


emcdonald on DSK2BSOYB1PROD with NOTICES